Global High potency active pharmaceutical ingredients Market Industry Analysis, Trends and Forecast to 2025

Global High potency active pharmaceutical ingredients Market research report identifies and analyses the emerging trends along with major drivers, inhibitors, challenges and opportunities in the market. With the specific base year and the historic year, estimations and calculations are performed in the report. Global High potency active pharmaceutical ingredients Market lets you know that how the market is going to perform in the forecast years by giving you information about market definition, classifications, applications, and engagements. All the statistical and numerical data, which is calculated with the most established tools such as SWOT analysis, is represented with the help of graphs and charts for the best user experience and clear understanding.

Global  High Potency Active Pharmaceutical Ingredients Market  is projected to reach USD 31.56 Billion by 2025, at a CAGR of 8.6% during the forecast period of 2018 to 2025.

FREE Sample report is instantly available at @

Market Segmentation: Global High potency active pharmaceutical ingredients Market

By Type

  • Innovative HPAI
  • Generic HPAI

By Type of Synthesis

  • Synthetic HPAI
  • Biotech HPAI

By Type of Manufacturer

  • Captive HPAI manufacturer
  • Merchant HPAI manufacturer

By Application

  • Oncology
  • Hormonal Imbalance
  • Glaucoma
  • Others

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

Report Can Be Provided as per Organization Requirement at @

Global High Potency Active Pharmaceutical Ingredients Market

High potency active pharmaceutical ingredients (HPAPI’s) the drugs which are highly effective in minute dosage than any generic API’s. HPAPI’s are classified on the basis of toxicity, pharmacological potency and occupational exposure limits. Generally HPAPI’s have very complex structure. Because of clinical pharmacology and research in oncology HPAPI’s have given more preference than API’s. When HPAPI’s combined with the antibody, the conjugate obtained  have specific targeting nature that targets only the cancerous cells without affecting the non-cancerous cells. The HPAPI’s have more annual growth than API’s. For manufacturing of HPAPI’s new pharmaceutical plants are established with new technologies. HPAPI’s has occupational exposure limit (OEL) of ≤10μg/m3, daily therapeutic dose of ≤10mg/day or if a 1 mg/kg/day dose produces serious toxicity in laboratory animals. Few HPAPI’s developed by few companies are hydromorphone hydrochloride, vinblastine sulfate, vincristine sulfate, vindesine sulfate, vinorelbine tartrate,


FREE TOC is available at @

Increasing Insistence Of Oncology Drugs

Cancer is the one the disease which is growing with a great prevalence rate. As per of World Cancer Research Fund International, in 2012 around 14.1 million cases were observed all over the world. This number is expected to increase to 24 million by 2035. As per of new stats produced by the Cancer research U. K in 2017 total deaths happened were 1,66,135 among this 45% deaths were because of Cancers only.  So by seeing this ratio to control the death from cancer new drug are required. HPAPI’s can play a major role in treating the cancer or other disease. Because of high action in minute amount the disease can be treated. HPAPI’s along with antibody had shown a significant action towards the cancerous cells without affecting the normal cells.

Increasing demand of Antibody-drug conjugate

When antibodies are joined with biologically active or chemical compound through chemical linkers. Antibody-drug conjugate have better action towards the cancerous cells than HPAPI’s because the HPAPI’s selectively targets the cancerous cells without affecting the normal healthy cells. Because of better mechanism of action of ADC than antibody or chemical drug, more research is going on for development of ADC’s which in turn enhances the HPAPI’s demand in the market.

Some of the major players operating in global high potency active pharmaceutical ingredients are

  • Catalent, Inc,
  • ANVI Pharma,
  • Farmhispania Group,
  • Quadro Engineering Corp,
  • SAFC,
  • Teva Pharmaceuticals industries Ltd ,
  • Bristol Myers Squibb,
  • Cambrex Ferro,
  • Carbogen Amcis.,
  • Mylan N.V.,
  • AbbVie Inc,
  • Eli Lilly and Company,
  • Boehringer Ingelheim International GmbH,
  • Hoffmann-La Roche,
  • Lonza, Alkermes,
  • Sanofi,

For more information about this report visit @

Show More